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Abstract
Aims/hypothesis An APOC3 promoter haplotype has been
previously associated with type 1 diabetes. In this
population-based study, we investigated whether APOC3
polymorphisms increase type 2 diabetes risk and need for
insulin treatment in lean participants.
Methods In the Rotterdam Study, a population-based
prospective cohort (n=7,983), Cox and logistic regression
models were used to analyse the associations and interac-
tive effects of APOC3 promoter variants (−482C>T,
−455T>C) and BMI on type 2 diabetes risk and insulin
treatment. Analyses were followed by replication in an
independent case–control sample (1,817 cases, 2,292
controls) and meta-analysis.
Results In lean participants, the −482T allele was associat-
ed with increased risk of prevalent and incident type 2
diabetes: OR −482CT 1.47 (95% CI 1.13–1.92), −482TT
1.40 (95% CI 0.83–2.35), p=0.009 for trend; HR −482CT
1.35 (95% CI 0.96–1.89), −482TT 1.68 (95% CI 0.91–3.1),
p=0.03 for trend, respectively. These results were con-
firmed by replication. Meta-analysis was highly significant
(−482T meta-analysis p=1.1×10
-4). A borderline signifi-
cant interaction was observed for insulin use among
participants with type 2 diabetes (−482CT*BMI p=0.06,
−455TC*BMI p=0.02).
Conclusions/interpretation At a population-based level, the
influence of APOC3 promoter variants on type 2 diabetes
risk varies with the level of adiposity. Lean carriers of the
−482T allele had increased type 2 diabetes risk, while such
an effect was not observed in overweight participants.
Conversely, in overweight participants the −455C allele
seemed protective against type 2 diabetes. The interaction
of the variants with need for insulin treatment may indicate
beta cell involvement in lean participants. Our findings
suggest overlap in the genetic backgrounds of type 1
diabetes and type 2 diabetes in lean patients.
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Abbreviations
ApoC-III Apolipoprotein C-III
IRE Insulin/phorbol ester responsive element
LPL Lipoprotein lipase
RS1 Rotterdam study
RSPlus1 Rotterdam study plus 1
Introduction
Type 2 diabetes mellitus is characterised by overweight,
impaired insulin secretion and insulin resistance [1]. Never-
theless, a substantial proportion of patients with type 2
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predominantly from impaired insulin secretion [4–6],
whereas obese patients would be more resistant to insulin
[7]. Defective insulin secretion has higher heritability
estimates than insulin resistance in family and twin studies
[8–10], and the concordance rate for type 2 diabetes in lean
twins is higher than that in obese twins [11]. This suggests
higher genetic susceptibility in lean type 2 diabetes and
involvement of pancreatic beta cell dysfunction.
Lean type 2 diabetes has a number of similarities to type 1
diabetes. Interestingly, type 1 diabetes is more frequent in
families with type 2 diabetes and vice versa [12, 13], a fact
that supports the hypothesis of genetic overlap between the
two diseases. In a paper by Hokanson et al., an APOC3
haplotype determined by two promoter polymorphisms
(−455T>C and −482C>T) was associated with type 1
diabetes [14]. Apolipoprotein C-III (ApoC-III) is an apoli-
poprotein involved in triacylglycerol metabolism. It inhibits
lipoprotein lipase (LPL) and mediates lipoprotein uptake by
the liver [15]. Higher ApoC-III production raises triacylgly-
cerol and NEFA levels, and thus may affect beta cell
function. [16, 17] On the other hand, ApoC-III has been
suggested to directly bring on beta cell death [18]. Located in
an insulin/phorbol ester responsive element (IRE), the
promoter polymorphisms curb the capacity of insulin to
downregulate the gene [19, 20]. In view of this evidence, we
hypothesised that polymorphisms in the APOC3 gene
increase susceptibility of lean individuals to type 2 diabetes
and that lean carriers of these polymorphisms with type 2
diabetes are more susceptible to insulin deficiency.
In the present population-based study, we investigated
whether the APOC3 −482C>T and −455T>C
polymorphisms influence type 2 diabetes risk in lean
persons. This was followed by replication testing in an
independent sample. In addition, we investigated the
associations with need for insulin treatment among type 2
diabetes participants from the Rotterdam Study (RS1).
Methods
Study population Details of the RS1 have been described
elsewhere [21]. In brief, the RS1 was a prospective,
population-based cohort study investigating determinants
of chronic diseases in the elderly. A total of 7,983
inhabitants of a Rotterdam suburb, aged 55 years or older,
were included. Baseline examinations were performed with
follow-up measurements at 1–3 year intervals. Linkage to
general practitioners’ records provided continuous monitor-
ing of major disease outcomes. Municipal health authorities
regularly provided information on vital status.
In accordance with the guidelines of the ADA [21, 22]
and WHO [23], diabetes was defined as a fasting plasma
glucose level ≥7.0 mmol/l and/or a non-fasting plasma
glucose level ≥11.0 mmol/l and/or treatment with oral
glucose-lowering medication or insulin, and diagnosis of
diabetes as registered by a general practitioner. Prevalent
cases of diabetes were diagnosed at baseline by a non-fasting
or post-load glucose level (after OGTT) ≥11.1 mmol/l and/or
treatment with oral glucose-lowering medication or insulin,
and by diagnosis of diabetes as registered by a general
practitioner.
For the present study, general practitioners’ records were
searched for type 1 diabetes diagnoses and these participants
were excluded. Data on insulin treatment were derived from
interviews at baseline and the pharmacy database, which
provided prospective data on prescribed insulin.
Written informed consent was obtained from all partic-
ipants and the Medical Ethics Committee of the Erasmus
Medical Center approved the study. For the present study,
baseline data were collected between 1990 and 1993.
Follow-up data were available until 1 October 2005.
Replication cohort The Rotterdam Study Plus 1 (RSPlus1)
(290 cases, 2,292 controls) and the DiaGene study (1,527
cases) were used as a combined replication cohort
(RSPlus1/DiaGene). RSPlus1 is an additional part of the
prospective population-based RS1 and has been described
in detail elsewhere [21]. The DiaGene study is an ongoing
collection of type 2 diabetes cases and controls from the
city of Eindhoven, the Netherlands. At the time of this
replication effort, 1,527 DiaGene cases were available for
genotyping. RSPlus1 and DiaGene cases were diagnosed
according to the guidelines of the WHO [23] and ADA
[21, 22], and/or based on treatment with oral glucose-
lowering medication or insulin. RSPlus1 and DiaGene
cases did not significantly differ in terms of age, sex and
BMI, and were combined in the analyses.
Writteninformedconsentwasobtainedfromallparticipants
and the Medical Ethics Committee of the Erasmus Medical
Center approved the study.
Genotyping In the APOC3 gene, the −482C>T(rs2854117)
and −455T>C (rs2854116) promoter polymorphisms were
chosen for genotyping on the basis of the ability to tag the
variation previously associated with type 1 diabetes, and
earlier associations with measures of glucose metabolism
and localisation in an IRE [14, 24–26].
Genotyping was performed with TaqMan allelic
discrimination assays designed and optimised by Applied
Biosystems (Foster City, CA, USA). Reactions were
performed on the TaqMan Prism 7900HT platform. The
duplicates mismatch rate was 0.003 and 0.02 in the RS1
and 0.018 and 0.044 in the RSPlus1/DiaGene cohorts for
the −482C>T and −455T>C polymorphisms, respectively.
Genotype success rates for −482C>T and −455T>C were
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Laboratory analyses In 3,930 participants fasting plasma
samples were available at the second follow-up visit of the
study for measurement of triacylglycerol. Triacylglycerol
levels were measured by enzymatic colorimetric methods
(CHOD-PAP and GPO-PAP; Boehringer Mannheim,
Mannheim, Germany) on an analyser (Hitachi 911;
Boehringer Mannheim).
Statistical methods Analyses were performed with SPSS
software version 16.0 (SPSS, Chicago, IL, USA). Linkage
disequilibrium was calculated with GOLD version 1.0.
(http://www.sph.umich.edu/csg/abecasis/GOLD/, accessed
1 January 2007). Continuous variables are expressed as
means ± SD. Comparisons between groups were performed
with independent samples t tests and χ
2 tests for normally
distributed continuous and categorical variables, respectively.
Triacylglycerol levels were not normally distributed and
therefore logarithmically transformed before the analyses.
ANOVA was used for comparison of continuous variables
between more than two groups. Deviations from Hardy–
Weinberg equilibrium were assessed by means of χ
2 testing.
Genotype frequencies were compared between incident and
prevalent cases, and participants without type 2 diabetes.
In RS1, we tested the associations of the genotypes with
type 2 diabetes and their interactions with BMI in logistic
regression models and prospectively in Cox proportional
hazards models for prevalent and incident type 2 diabetes,
respectively. Participants with prevalent type 2 diabetes at
baseline were excluded from the prospective analyses.
In the RSPlus1/DiaGene cohort we repeated the analyses
described above using logistic regression. Haplotype
analyses did not add any further information on analyses
of the individual genotypes and are therefore not shown
here.
To test the hypothesis of beta cell involvement, we
tested the associations of genotypes with insulin treat-
ment and their interactions with BMI in a logistic
regression model in RS1 in patients with type 2 diabetes.
Prevalent and incident insulin use was included in these
analyses. Linear regression models were used to analyse
the association between the polymorphisms and fasting
triacylglycerol levels. All models were adjusted for year
of birth and sex.
All analyses described above were repeated in two
subgroupsstratifiedforBMIusingtheRS1populationmedian.
Lean persons had a BMI equal to or below 26 kg/m
2 and
overweight persons had a BMI above 26 kg/m
2.
The p values found in RS1 and RSPlus1/DiaGene were
combined by a Z-based meta-analysis using beta, standard
error and number of participants of each cohort.
Combining RS1 and RSPlus1/DiaGene, we had 98%
power to detect an effect of OR 1.3 (minor allele frequency
0.20) in the lean group (n=802 cases, i.e. the smallest
group of cases analysed for type 2 diabetes).
Results
Baseline characteristics RS1 Diabetes status was available
for 6,362 successfully genotyped persons. Participants
whose genotyping was not successful or whose DNA was
not available were 5.8 years older and included 8.5% more
women. Nevertheless, the genotyped and not genotyped
groups had similar distributions of BMI, waist circumference
and presence of type 2 diabetes.
Participants with type 2 diabetes (prevalent and incident)
had significantly higher BMI and waist circumference, and
lower HDL-cholesterol, than those without type 2 diabetes
(Table 1). Prevalent cases were significantly older and had
significantly lower BMI than incident cases.
Population genetics In the total population and BMI
subgroups, the polymorphisms were in Hardy–Weinberg
equilibrium (χ
2<3.35, df 1, p>0.07). Heterozygosity for the
−482 T allele was found in 34.6% of participants; 5.9%
were homozygous. For the −455C allele these percentages
were 43.0% and 12.6%, respectively. There was a strong
linkage disequilibrium between the two polymorphisms,
D′=0.968 (p<0.000001), r
2=0.54. Frequencies of geno-
types did not differ significantly between participants with
and without type 2 diabetes, or between incident and
prevalent cases in the total population (data not shown).
We identified four haplotypes, H1 to H4, according to
decreasing population frequency. H1 was defined by the
absence of both minor alleles, H2 by the presence of both
minor alleles, H3 by only the presence of the −455 minor
allele and H4 by the presence of the −482 minor allele. The
allele frequencies of H1, H2 and H3 were 64.4%, 23.4%
and 11.8%, respectively.
Type 2 diabetes risk in lean and overweight persons In the
total population, none of the genotypes significantly influenced
the risk of type 2 diabetes. Adjustment for BMI and waist
circumference did not change these results (data not shown).
We observed an effect of the interaction of −482C>T
and −455T>C polymorphisms with BMI on prevalent type 2
diabetes (−482C>T*BMI, p=0.01; −455T>C*BMI
p=0.01). Similar findings were observed prospectively for
effect on the risk of incident type 2 diabetes (−482C>
T*BMI, p=0.002; −455T>C*BMI, p=0.03).
Table 2 shows ORs for prevalent type 2 diabetes and
HRs for incident type 2 diabetes according to APOC3
promoter genotype in lean and overweight persons. In lean
1362 Diabetologia (2011) 54:1360–1367participants, the −482T allele was associated with increased
risk of diabetes (−482CT OR 1.47, −482TT OR 1.40, p=
0.009 for trend). Similar results were found in prospective
analyses (−482CT HR 1.35 [95% CI 0.96–1.89], −482TT
HR 1.68 [95% CI 0.91–3.1]; p=0.03 for trend). The
−455T>C polymorphism showed similar associations in
lean participants.
In overweight participants, no significant effects of the
−482C>T polymorphism on diabetes risk was observed,
while carriers of the −455C allele had lower prospective risk
of type 2 diabetes (−455TC HR 0.88 [95% CI 0.71–1.1],
−455CC HR 0.70 [95% CI 0.49–0.998], p=0.04 for trend).
Replication and meta-analysis Baseline characteristics of
the RSPlus1/DiaGene cohort are shown in Table 3. Cases
were older (p<0.001), had higher BMI (p<0.001) and were
more often men (p<0.001) than controls. In the replication
analyses, we found similar results to the original cohort, in
Table 1 RS1 baseline characteristics of all participants and patients with and without type 2 diabetes
Characteristics All participants Without diabetes Prevalent cases Incident cases p value
N 6,362 5,156 661 545
Age (years) 69.4±9.1 69±9.1 73.5±9.2 68.4±7.9 <0.001
a,b
Men (%) 40.6 40.4 39.5 44 NS
BMI (kg/m
2) 26.3±3.7 26.0±3.6 26.8±4.1 28.1±3.7 <0.001
a,b,c
Total cholesterol (mmol/l) 6.6±1.2 6.6±1.2 6.5±1.2 6.6±1.2 NS
Triacylglycerol (mmol/l) 1.53±0.01 1.47±0.01 1.83±0.07 1.89±0.05 <0.001
a,c
HDL-cholesterol (mmol/l) 1.34±0.37 1.37±0.37 1.25±0.37 1.25±0.34 <0.001
b,c
Age at diagnosis (years) NA NA 68.6±0.50 74.8±0.34 <0.001
b
Values are means±standard errors unless otherwise indicated
aFor comparison between prevalent cases and participants without diabetes;
bfor comparison between incident cases and prevalent cases;
cfor comparison
between incident cases and participants without diabetes
NA, not applicable
Table 2 HRs and ORs for incident and prevalent type 2 diabetes, replication and meta-analysis for APOC3 genotypes in lean and overweight
participants
Variants RS1 HR RS1 OR Replication cohort Overall
Polymorphisms
per BMI
Genotype Incident
diabetes
a
95% CI p trend Prevalent
diabetes
a
95% CI p trend OR
b 95% CI p trend p value
c
BMI≤26 kg/m
2
−482C>T CC 1.0 1.0 1.0
CT 1.35 (0.96–1.89) 1.47 (1.13–1.92) 1.06 (0.81–1.38)
TT 1.68 (0.91–3.1) 0.03 1.40 (0.83–2.35) 0.009 1.99 (1.25–3.16) 0.03 1.1×10
-4
−455T>C TT 1.0 1.0 1.0
TC 1.27 (0.89–1.8) 1.65 (1.24–2.20) 0.86 (0.66–1.13)
CC 1.39 (0.85–2.28) 0.1 1.40 (0.92–2.13) 0.01 1.09 (0.74–1.62) 0.9 0.04
BMI >26 kg/m
2
−482C>T CC 1.0 1.0 1.0
CT 1.04 (0.84–1.28) 0.85 (0.66–1.10) 1.04 (0.88–1.23)
TT 0.56 (0.32–0.98) 0.3 0.84 (0.51–1.39) 0.22 1.47 (1.08–1.99) 0.05 0.73
−455T>C TT 1.0 1.0 1.0
TC 0.88 (0.71–1.1) 0.98 (0.76–1.25) 0.90 (0.76–1.06)
CC 0.70 (0.49–0.998) 0.04 0.71 (0.48–1.06) 0.16 0.79 (0.62–1.02) 0.05 0.003
aAdjusted for year of birth and sex
bAdjusted for age and sex
cMeta-analyses p value combining RS1 and RSPlus1/DiaGene
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lean persons (−482CT 1.06 [95% CI 0.81–1.38], −482TT
1.99 [95% CI 1.25–3.16]; p=0.03 for trend). No significant
effects were found for the −482C>T and −455T>C poly-
morphisms in overweight participants (p=0.05 for trend for
both).
In meta-analyses, the effect of the −482T allele in lean
participants was confirmed (p=1.1×10
−4 in meta analysis).
In overweight participants, a protective effect of the −455C
allele seemed to be present (p=0.003)
Insulin treatment in lean and overweight participants
Table 4 shows the ORs for insulin treatment among
participants with diabetes, according to the −482C>T and
−455T>C genotypes. None of the ORs was statistically
significant in this small group of participants. However, there
was a borderline significant interaction of the −482C>T
polymorphism with BMI in participants with diabetes
(−482C>T*BMI, p=0.06) and a significant interaction for
the −455T>C polymorphism (−455T>C*BMI, p=0.02).
Intermediate traits The genotypes were not associated with
BMI (−482C>T, p=0.60; −455T>C, p=0.21) or fasting
triacylglycerol levels (−482C>T, p=0.67; −455T>C,
p=0.73). They were also not associated with fasting
triacylglycerol levels within the high and low BMI groups
(data not shown).
Discussion
Main findings In this population-based study, we found
significant interactions between BMI and genetic variants
in the APOC3 promoter for type 2 diabetes risk. Lean
participants carrying the −482T allele had higher risk of
type 2 diabetes. These results were replicated in an
independent population. Moreover, APOC3 promoter var-
iants showed a borderline significant interaction with BMI
for the need for insulin therapy. Presence of the minor
alleles showed a trend towards increased need for insulin
therapy in lean participants. Conversely, in overweight
participants the −455C allele seemed protective against type
2 diabetes.
The RS1 study design included meticulous follow-up on
disease outcomes over a long time. The large number of
diabetic cases enabled us to replicate the findings within
our population in prevalent and incident cases. Moreover,
we were able to replicate and meta-analyse the findings by
means of an independent population. Information on insulin
treatment provided an important intermediate phenotype for
the interpretation of our findings and the understanding of
pathophysiological mechanisms. To our knowledge, this is
the first study that shows an interaction between APOC3
variants and BMI to have an effect on type 2 diabetes risk.
Our results show that the effect of variation in the
APOC3 gene is context-dependent. Our findings are not in
Characteristics All participants
a Controls Cases p value
n 4,134 2,292 1,817
Age (years) 65.5±9.0 64.4±7.8 66.8±10.1 <0.001
Men (%) 48.4 44.3 53.7 <0.001
BMI (kg/m
2) 28.4±4.9 26.9±3.9 30.4±5.3 <0.001
Table 3 Baseline characteristics
from the RSPlus1/DiaGene
sample
Unless otherwise shown, values
are means ± standard error
aDiabetes status missing for
25 participants
Polymorphism per BMI Genotype OR
a 95% CI p value for trend
BMI ≤26 kg/m
2b
−482C>T CC Reference
CT 1.49 (0.89–2.49)
TT 1.66 (0.68–4.00) 0.11
−455T>C TT Reference
TC 1.71 (0.95–3.08)
CC 1.64 (0.74–3.62) 0.13
BMI >26 kg/m
2c
−482C>T CC Reference
CT 0.94 (0.63–1.41)
TT 1.26 (0.53–3.03) 0.92
−455T>C TT Reference
TC 0.83 (0.56–1.25)
CC 0.78 (0.40–1.55) 0.34
Table 4 Odds ratios for insulin
treatment in lean and overweight
participants with diabetes in
RS1
aAdjusted for year of birth and
sex
bInsulin-treated n=83,
non-insulin-treated n=344
cInsulin-treated n=131,
non-insulin-treated n=575
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Barker hypothesis [28]. APOC3 variants were not associ-
ated with BMI. The common APOC3 variants have an
intricate relationship with type 2 diabetes. We hypothesise
that lean type 2 diabetes has a distinct molecular basis of its
own or that it shares part of its aetiology with type 1
diabetes.
Previous studies Hokanson and colleagues found the
APOC3 promoter variants to be associated with suscepti-
bility to type 1 diabetes [14]. Our findings in the lean type 2
diabetes group are consistent with this finding, with ORs of
similar magnitude and direction. Lean type 2 diabetes and
type 1 diabetes may both have insulin deficiency as the
main characteristic. A partly shared aetiology or at least
genetic overlap in disease susceptibility may also explain
the increased frequency of lean type 2 diabetes in families
with type 1 diabetes and vice versa [12, 13]. Patients with
type 2 diabetes who have relatives with type 1 diabetes are
leaner and have lower C-peptide concentrations than those
with a family history of type 2 diabetes [29].
Our finding that lean carriers of the minor alleles may
require insulin therapy more frequently points towards an
effect of APOC3 variants on beta cell function. Neverthe-
less, the disease process could also involve insulin
resistance. The EARS II study reported larger AUCs for
glucose and insulin in carriers of the −482T allele after an
OGTT [24]. The population of this study consisted of
young, healthy, lean offspring of men with premature
cardiovascular disease. It would follow therefore that
APOC3 promoter variation increases insulin resistance at
a young age, possibly resulting in type 2 diabetes and an
earlier need for insulin therapy. Nevertheless, caution
should be exercised when extrapolating differences in
insulin and glucose AUCs in young healthy participants to
relevance for diabetes risk at an older age. In a study of
middle-aged participants, male homozygotes of the variant
promoter alleles showed less increase in insulin levels after
an OGTT [26]. This is in line with our findings in lean
participants.
Pathophysiological hypotheses Strikingly, we found an
opposite effect of APOC3 promoter variation in overweight
participants, in whom it would seem to protect against type 2
diabetes. Possibly competing risks overruled the effect of the
APOC3 polymorphism and even resulted in an inverse
association in overweight participants. Alternatively, there
could be a pathophysiological explanation based on the
metabolic differences between lean and overweight
patients. In lean participants, our findings could be
explained as follows. The presence of the promoter poly-
morphisms results in insulin resistance at a molecular level;
thus the insulin-resistant APOC3 promoter shows impaired
insulin-mediated downregulation [19, 20]. Increased
ApoC-III plasma levels have been described in type 2
diabetes, but were mostly interpreted as a consequence of
the disease [30, 31]. A direct toxic effect of ApoC-III on
beta cells was found in in vitro studies by Juntti-Berggren
et al. [18]. Indirect mechanisms involving lipoprotein
metabolism might play a role, too. However, we did not
find an association of the promoter variation with fasting
triacylglycerol levels. This, however, does not exclude an
effect of the polymorphisms on NEFA flux. Defective
inhibition of LPL by ApoC-III might raise levels of
circulating NEFAs and thus affect insulin sensitivity and
beta cell function [17, 32, 33].
In overweight participants, hyperinsulinaemia may partly
restore the insulin-mediated downregulation and may
prevent beta cell toxicity. Nonetheless we do not have a
clear explanation for a protective effect. A number of
studies have shown that LPL metabolism may differ
between lean and obese participants. However, it is
unknown how differences in lipoprotein composition [34]
or post-translational regulation of LPL [35–37] influence
susceptibility to type 2 diabetes. Taken together, APOC3
promoter variation may directly affect beta cell function in
lean participants and reduce type 2 diabetes risk in
overweight participants by mechanisms that are at present
unknown. Alternatively, it may affect type 2 diabetes risk in
lean and obese individuals in opposing ways and by
mechanisms that involve LPL function.
Study limitations Some limitations of our study need to be
considered. Unfortunately, we could not compare our
findings with currently published genome-wide association
studies, since they were not publicly available for lean and
overweight participants separately. We also cannot exclude
the possibility that the observed effects are due to linkage
disequilibrium with other variants in the APOC3 gene or
other nearby genes in the APOA1–APOC3–APOA4–APOA5
cluster. Nonetheless, the localisation in an IRE, their
defective insulin-mediated downregulation in vitro and the
findings by Hokanson and colleagues in type 1 diabetes [14]
make these polymorphisms likely candidates for type 2
diabetes susceptibility in lean participants. Another limitation
of the study is the relatively small group of participants in
which we found a borderline significant interaction for
insulin use. Although these results can help focus hypotheses
on the mechanism by which APOC3 polymorphisms affect
type 2 diabetes risk, a type 1 error cannot be excluded. These
results are merely an encouragement for further research
replication in independent cohorts.
Conclusion Our findings indicate that APOC3 promoter
variants significantly interact with BMI at a population-
based level, increasing type 2 diabetes risk in lean and
Diabetologia (2011) 54:1360–1367 1365possibly decreasing type 2 diabetes risk in overweight
patients. The borderline interaction of the promoter variants
with need for insulin treatment suggests beta cell function
involvement inlean participants. Our results suggest a genetic
overlap between type 1 and lean type 2 diabetes. A subset of
type 2 diabetes has already been identified for patients with
auto-antibodies, i.e. type 1.5 diabetes or Latent autoimmune
diabetes of adulthood [38]. It would seem unlikely that
ApoC-III is related to autoimmunity. Our findings may
therefore relate to a different subgroup of lean diabetes
patients that shows genetic overlap with type 1 diabetes.
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